Tg129V (1st pass.) |
Inoculum | VV120 | VV121 | VV121−20* | VV2 |
Attack rate (%) | 100 | 100 | 100 | 100 |
Incubation (dpi) | 351 ± 16 | 425 ± 66 | 315 ± 66 | 215 ± 18 |
resPrPD replicated | T120 (To-2 -) | T121 (To-2 -) | T121 (To-2 +) | T2 (To-2 +) |
Tg129M (1st pass.) |
Inoculum | VV120 | VV121 | VV121−20* | VV2 |
Attack rate (%) | 100 | 0 | 100 | 100 |
Incubation (dpi) | 554 ± 53 | 0 | 570 ± 60 | 626 ± 56 |
resPrPD replicated | T121−20 (To-2 -) | No transmis | T121−20 (To-2 +) | T120 (To-2 -) |
Tg129M (2nd pass.) |
Inoculum | VV120 | VV121 | VV121−20* | ND |
Attack rate (%) | 100 | 0 | 100 | ND |
Incubation (dpi) | 338 ± 30 | 0 | 292 ± 16 | ND |
resPrPD replicated | T121−20 (To-2: ND) | No transmis | T121−20 (To-2: ND) | ND |
- resPrPD: proteinase K (PK)-resistant PrPD; dpi: days post-inoculation (mean value ± standard deviation). Tohoku-2 positive (To-2 +) or negative (To-2 −) immunoreactivity. VV121−20*: sCJDVV1-2 with T2 accounting for ~ 5% of total resPrPD. Dpi (1st pass.), Tg129V: VV2 vs. VV120, P < 0.0008; VV2 vs. VV121, P < 0.04; VV120 vs. VV121 or VV121−20*, P > 0.05. Dpi (1st pass.), Tg129M: VV2 vs. VV120, P < 0.03; VV2 vs. VV121–20* and VV120 vs. VV121−20*, P > 0.05; Dpi (2nd pass.), Tg129M: VV120 vs. VV121−20*, P < 0.009. Dpi, Tg129M: 1st vs. 2nd passage of VV120 or VV121−20*, P < 0.0001. Statistical significance was determined by one-way ANOVA and Student’s t-test. No transmis.: no transmission; pass.: passage; ND: not done